Treatment of HER2-Expressing Breast Cancer and Ovarian Cancer Cells With Alpha Particle-Emitting 227Th-Trastuzumab

Targeted use of Alpha Particles: Current Status in Cancer Therapeutics

“…227 Th, when coupled to Trastuzumab, has been demonstrated to have a highly toxic effect against individual tumor cells in vitro, decreasing survival, inhibiting growth and inducing apoptosis in HER2-overexpressing cells [58]. In a preclinical study, mice implanted with HER-2-positive breast cancer xenografts were intravenously injected with -Trastuzumab demonstrated a dose-dependent increase in survival compared to those in the control group, with mean survival time nearly doubling with the administration of the highest dose, 600 kBq/kg [59]. When a 227 Th atom decays into its daughter nuclides, it detaches from Trastuzumab, and loses its anchor to the HER2-expressing tumor cell.…”

HER2 as a Therapeutic Target in Ovarian Cancer

“…HER2 antibodies can be conjugated with other anticancer drugs or radioactive entities to target chemotherapy and radiotherapy to cancerous cells that express HER2. Radiolabeled trastuzumab and pertuzumab have both been shown to delay tumor progression in mice with SKOV3 xenografts (Palm et al, 2007;Persson et al, 2007) and reduce the growth of SKOV3 cells in vitro (Heyerdahl et al, 2011), while trastuzumab-platinum (II) conjugates have been shown to increase SKOV3 cell death in vitro (Gao et al, 2008). Trastuzumab-DM1 (T-DM1) conjugates enable the targeted delivery of the antimicrotubule agent DM1 to cancer cells overexpressing HER2.…”

Targeted imaging of ovarian cancer cells using viral nanoparticles doped with indocyanine green

“…HER-2 targeting has been achieved by targeted nanoparticles as well as fluorophore-conjugated antibodies [8][9][10][11][12][13]. Our nanoparticle formulation provides a new approach which has proven to effectively target and selectively label ovarian cancer cells with high-HER-2 expression levels.…”